Evaluating sarcopenia in lymphoma patients receiving CAR-T therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to assess sarcopenia and simplified geriatric assessment (sGA) as potential predictors of treatment efficacy and toxicity in adult patients with B-cell non-Hodgkin lymphoma undergoing CAR-T cell therapy. Participants will be evaluated based on their physical condition and treatment outcomes, utilizing pre-treatment imaging to gather relevant data. The study seeks to identify factors that may influence the success of CAR-T therapy in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years old).
* Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
* Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART
* Written informed consent voluntarily provided

Exclusion Criteria:

* Patients not fulfilling the eligibility criteria

Where it's running

• A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia
  Alessandria, Italy Recruiting
• AOU Ospedali Riuniti - Clinica di Ematologia
  Ancona, Italy Recruiting
• Azienda Ospedaliera S .Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico
  Avellino, Italy Recruiting
• IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati
  Aviano, Italy Recruiting
• ASST Spedali Civili di Brescia - S.C. Ematologia
  Brescia, Italy Recruiting
• Ospedale di Castelfranco Veneto - Oncoematologia IOV
  Castelfranco Veneto, Italy Recruiting

Study contacts

• Principal investigator: Vittorio Ruggero Zilioli — ASST Grande Ospedale Metropolitano Niguarda
• Study coordinator: Uffici Studi FIL
• Email: startup@filinf.it
• Phone: +390131033153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Universal CAR-T therapy for CD19-positive B‑cell non-Hodgkin lymphoma

  This study will try an off‑the‑shelf CAR‑T product called BRL‑301 in adults with CD19‑positive B‑cell non‑Hodgkin lymphoma to see if a single 5×10^6/kg dose is safe and shows anti‑tumor activity.

  Recruiting Bioray Laboratories · Shanghai · NCT07248163

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

• Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma

  This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT06834373

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.